ArticleCommunications biology2025
A programmable pAgo nuclease with high activity and specificity for efficient DNA and RNA manipulation.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prokaryotic Argonaute proteins (pAgos) are programmable nucleases with potential for the development of novel nucleic acid manipulation tools. Previous studies have shown that several pAgos exhibit strong preferences for either DNA or RNA targets, and effective cleavage of plasmid or linear double-stranded DNA (dsDNA) is typically limited to regions with low GC content. Here, we characterize a pAgo, GgeAgo from the thermophilic organism Geobacillus genomosp. 3. GgeAgo utilizes 5' phosphorylated DNA guides to cleave both DNA and RNA with high efficiency and specificity under a wide range of conditions. Notably, GgeAgo efficiently cleaves both plasmid and linear dsDNA with GC content up to 53% at elevated temperatures, and retains detectable activity even at 64% GC. Furthermore, GgeAgo demonstrates robust activity in practical applications, including DNA cloning, nucleic acid detection, and enrichment of rare variants, with high specificity and sensitivity. These results suggest that GgeAgo holds promise as an effective DNA and RNA manipulation tool for biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.